Cargando…

Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study

OBJECTIVES: Development of pharmaceutical agents in transplantation is currently limited by long waits for hard endpoints. We applied a validated integrative risk-prognostication system integrative Box (iBox) as a surrogate endpoint to the TRANSFORM Study, a large randomised controlled trial, to pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aubert, Olivier, Divard, Gillian, Pascual, Julio, Oppenheimer, Federico, Sommerer, Claudia, Citterio, Franco, Tedesco, Helio, Chadban, Steve, Henry, Mitchell, Vincenti, Flavio, Srinivas, Titte, Watarai, Yoshihiko, Legendre, Christophe, Bernhardt, Peter, Loupy, Alexandre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Renal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499283/ https://www.ncbi.nlm.nih.gov/pubmed/34620664 http://dx.doi.org/10.1136/bmjopen-2021-052138

Ejemplares similares

Qualifying a Novel Clinical Trial Endpoint (iBOX) Predictive of Long-Term Kidney Transplant Outcomes
por: Klein, Amanda, et al.
Publicado: (2023)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

The impact of blended learning on students using the IBOX platform: Initial perspectives of teachers
por: Barfi, Kwaku Anhwere, et al.
Publicado: (2023)

Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin – study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients
por: Singer, Julian, et al.
Publicado: (2022)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Protocol for a pilot single-centre, parallel-arm, randomised controlled trial of dietary inulin to improve gut health in solid organ transplantation: the DIGEST study
por: Singer, Julian, et al.
Publicado: (2021)

Living kidney donor and recipient perspectives on their relationship: longitudinal semi-structured interviews
por: Ralph, Angelique F, et al.
Publicado: (2019)

Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation
por: Naesens, Maarten, et al.
Publicado: (2022)

Inflammatory Response to Sorbent Hemodialysis
por: Rosales, Laura, et al.
Publicado: (2015)

Dietary sodium induces a redistribution of the tubular metabolic workload
por: Udwan, Khalil, et al.
Publicado: (2017)

VEGF‐A(165)b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF‐A splice isoforms from the kidney
por: Stevens, Megan, et al.
Publicado: (2017)

RAAS inhibitors directly reduce diabetes‐induced renal fibrosis via growth factor inhibition
por: Koszegi, Sandor, et al.
Publicado: (2018)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Referral patterns, disease progression and impact of the kidney failure risk equation (KFRE) in a Queensland Chronic Kidney Disease Registry (CKD.QLD) cohort: a study protocol
por: Mutatiri, Clyson, et al.
Publicado: (2022)

Comparison of artificial intelligence and human-based prediction and stratification of the risk of long-term kidney allograft failure
por: Divard, Gillian, et al.
Publicado: (2022)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial
por: Morath, Christian, et al.
Publicado: (2022)

Statistical evaluation of surrogate endpoints: a systematic review
por: Ensor, Hannah, et al.
Publicado: (2013)

Bivariate network meta‐analysis for surrogate endpoint evaluation
por: Bujkiewicz, Sylwia, et al.
Publicado: (2019)

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
por: Medeiros, Felipe A.
Publicado: (2017)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria
por: Jeeyapant, Atthanee, et al.
Publicado: (2017)

Surrogate endpoints and competing risk of death in cardiac arrest research
por: McCredie, Victoria A., et al.
Publicado: (2016)

Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints
por: Bujkiewicz, Sylwia, et al.
Publicado: (2015)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
por: Lathia, Chetan D.
Publicado: (2002)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
por: Bikdeli, Behnood, et al.
Publicado: (2017)

Binary surrogate endpoints in clinical trials from the perspective of case definitions
por: HAHN, ANDREAS, et al.
Publicado: (2021)

A call for better reporting of trials using surrogate primary endpoints
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
por: Ciani, Oriana, et al.
Publicado: (2023)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vqgpvv6d423a2383ocgklirme1